Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome.
Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome.
复制标题
DOI：
10.1111/j.1399-5618.2010.00823.x
复制
发表时间：
2010-06
影响因子：
5.4
通讯作者：
Calabrese JR
中科院分区：
文献类型：
--
作者：
Kemp DE;Gao K;Chan PK;Ganocy SJ;Findling RL;Calabrese JR
本研究检查了躁郁症中的医学烧伤与疾病严重程度的几个指标和预后的指标。瓣膜。
从两项评估锂和丙丙酸酯的研究中分析了双极I和II疾病的快速循环表现。医疗伯恩，体重指数（BMI），药物使用障碍状态和抑郁症状严重程度。
在225名患者中，有41.8％的患者患有50.7％的男性，而69.8％的样本疾病的平均年龄为36.8（SD = 10.8）。每名患者为2.5（SD = 2.5），平均CIRS总分为4.3（SD = 3.1）。受医学疾病的影响（p = 0.04）。 ，响应的可能性降低了7.5％[优势比（OR）= 0.93，95％置信区间（CI）：0.87-0.99；减少7.3％（OR = 0.93，95％CI：0.87–0.99; p = 0.03）。较低的反应几率，但仅在BMI≥23的患者中（p = 0.02）。
在接受锂和丙戊酸酸酯和丙丙酸酯的快速循环疾病的患者中，内分泌/代谢疾病（包括超重和肥胖症）似乎与更大的抑郁症状严重程度和较差的治疗结果有关。
The present study examined the relationship between medical burden in bipolar disorder and several indicators of illness severity and outcome. It was hypothesized that illnesses of the endocrine/metabolic system would be associated with greater psychiatric symptom burden and would impact the response to treatment with lithium and valproate. Data were analyzed from two studies evaluating lithium and valproate for rapid-cycling presentations of bipolar I and II disorder. General medical comorbidity was assessed by the Cumulative Illness Rating Scale (CIRS). Descriptive statistics and logistic regression analyses were conducted to explore the relationships between medical burden, body mass index (BMI), substance use disorder status, and depressive symptom severity. Of 225 patients enrolled, 41.8% had a recent substance use disorder, 50.7% were male, and 69.8% had bipolar I disorder. The mean age of the sample was 36.8 (SD = 10.8) years old. The mean number of comorbid medical disorders per patient was 2.5 (SD = 2.5), and the mean CIRS total score was 4.3 (SD = 3.1). A significant positive correlation was observed between baseline depression severity and the number of organ systems affected by medical illness (p = 0.04). Illnesses of the endocrine/metabolic system were inversely correlated with remission from depressive symptoms (p = 0.02), and obesity was specifically associated with poorer treatment outcome. For every 1-unit increase in BMI, the likelihood of response decreased by 7.5% [odds ratio (OR) = 0.93, 95% confidence interval (CI): 0.87–0.99; p = 0.02] and the likelihood of remission decreased by 7.3% (OR = 0.93, 95% CI: 0.87–0.99; p = 0.03). The effect of comorbid substance use on the likelihood of response differed significantly according to baseline BMI. The presence of a comorbid substance use disorder resulted in a lower odds of response, but only among patients with a BMI ≥ 23 (p = 0.02). Among patients with rapid-cycling bipolar disorder receiving lithium and valproate, endocrine/metabolic illnesses, including overweight and obesity, appear to be associated with greater depressive symptom severity and poorer treatment outcomes.
登录
查看更多内容
影响因子：
7.2
作者：
Hudon, C;Fortin, A;Vanasse, A
通讯作者：
Vanasse, A
影响因子：
1.2
作者：
Kawahara, S;Akashiba, T;Horie, T
通讯作者：
Horie, T
影响因子：
5.4
作者：
Correll, Christoph U.;Frederickson, Anne M.;Manu, Peter
通讯作者：
Manu, Peter
影响因子：
5.3
作者：
Elmslie, JL;Silverstone, JT;Romans, SE
通讯作者：
Romans, SE
DOI：
10.1111/j.1532-5415.1968.tb02103.x
发表时间：
1968-01-01
影响因子：
6.3
作者：
LINN, BS;LINN, MW;GUREL, L
通讯作者：
GUREL, L